Carlos Becerra, MD, discusses the current management and emerging therapies for patients with pancreatic cancer.
Carlos Becerra, MD
Treatment with chimeric antigen receptor (CAR) T cells induced a significant decrease in tumor burden in patients with metastatic pancreatic cancer, despite low response rates, according to Carlos Becerra, MD.
Investigators are aiming to expand on the data with CAR T-cell therapy with an ongoing phase I study exploring CAR T-cell therapy in patients with unresectable pancreatic cancer (NCT02744287). This study is designed to determine the safety of the administration of antiprostate stem cell antigen CAR T cells. Additionally, it aims to evaluate the safety of rimiducid infusion after CAR T-cell therapy is administered, as well as the persistence of the CAR T cells over time after a single rimiducid infusion. This study is currently enrolling patients and is estimated to be completed in 2020.
Additional approaches, including checkpoint inhibitors and novel chemotherapy regimens, are also being explored in this landscape.
In an interview withTargeted Oncology, Becerra, a physician at Texas Oncology, discussed the current management and emerging therapies for patients with pancreatic cancer.
TARGETED ONCOLOGY:Can you provide an overview of your presentation on the management of pancreas cancer?
Becerra:Pancreas cancer is one of the leading causes of death related to cancer. We do not have good treatments. We have made some progress in pancreas cancer, particularly with metastatic disease, since many patients present to an oncologist already with metastatic disease.
We have made some progress over the past 7 or 8 years with the new chemotherapeutic agents. We have been investigating the sequencing of the agents to improve overall survival. It is not uncommon today to see patients 15 to 20 months after they have been diagnosed who are alive and doing well. That speaks to the fact that the newer agents are doing the work. However, we need to go beyond that.
The new era of targeted therapy and immunotherapy is going to provide the additional benefits that we need for our patients with metastatic pancreas cancer.
TARGETED ONCOLOGY:Is there a role for checkpoint inhibitors in this field?
Becerra:The immune checkpoint inhibitors pembrolizumab (Keytruda) and nivolumab (Opdivo) are being studied in pancreas adenocarcinoma. We think that there is a subgroup of patients who might benefit the most. These are the patients whose tumors are microsatellite instability-high (MSI-H). We are currently studying those patients as they become our target population.
[Pembrolizumab] has been approved across the board for all MSI-H tumors. [There is a subgroup of patients with] MSI-H tumors who have metastatic pancreas cancer.
TARGETED ONCOLOGY:Are there any ongoing trials that are showing promise?
Becerra:There are several trials that we are excited about. As we break down the molecular makeup in mutations that occur in pancreas cancer, there is a subgroup of patients who have mutations that we think might be targetable.
In addition to that, we are heavily studying immunotherapy in these patients. We are looking to discover if there will be immune checkpoint inhibitors in combination or CAR T cells that have been modified to recognize a specific target in the tumor to attack.
TARGETED ONCOLOGY:What data have been shown with CAR T cells?
Becerra:There are very little data available. There is a study conducted from the investigators at the University of Pennsylvania investigating CAR T cells directed against mesothelin. It was presented by Dr Gregory L. Beatty at the 2017 ASCO Annual Meeting. It showed some interesting results. Although the response rate was low, there were responses in patients with metastatic disease whose tumor burden decreased significantly after being treated with CAR T cells.
We are currently conducting a study at Baylor College of Medicine with CAR T cells directed against a different target. This study has a spin to it which is using an activating agent called rimiducid for patients with metastatic pancreas cancer who have progressed on first-line chemotherapy.
TARGETED ONCOLOGY:Where do you envision the treatment landscape heading in the next 5 years?
Becerra:I see that chemotherapy is here to stay. We already have several backbones of chemotherapy that we can use. In addition to that, targeted therapies are making their way into a subpopulation of patients whose tumors have certain mutations.
In addition to that, we are exploring and expanding immunotherapy to attempt to improve the outcomes. In the next 5 years, there will be combinations of different regimens to improve the overall outcomes of our patients.
TARGETED ONCOLOGY:Is there anything else that you would like to add?